<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120132</url>
  </required_header>
  <id_info>
    <org_study_id>FOV1101/CLIN202</org_study_id>
    <secondary_id>10-003-03</secondary_id>
    <nct_id>NCT01120132</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Administration of FOV1101-00 (Cyclosporine Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Mild Ongoing Ocular Allergic Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fovea Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fovea Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of the administration of
      cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic
      conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diary assessment of signs and symptoms of ocular allergy</measure>
    <time_frame>During the 28 days of treatment</time_frame>
    <description>Patient-reported ocular itching and redness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diary and office assessments of various ocular and nasal allergy signs and symptoms</measure>
    <time_frame>During 28 days of treatment</time_frame>
    <description>Patient-reported ocular itching and redness, lid swelling, tearing and nasal itching
Investigator assessments of ocular redness and chemosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>During the 28 days of treatment</time_frame>
    <description>Ocular tolerance and adverse events</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">716</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Cyclosporine low dose , Prednisolone Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine high dose, Prednisolone Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of a solution of Cyclosporine (high dose) and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of a solution of Cyclosporine (low dose) and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone Acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of a suspension of Prednisolone Acetate and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA high dose</intervention_name>
    <description>Solution of Cyclosporine (high dose) administered during 28 days</description>
    <arm_group_label>Cyclosporine high dose, Prednisolone Acetate</arm_group_label>
    <arm_group_label>Cyclosporine high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA low dose</intervention_name>
    <description>Solution of Cyclosporine (low dose) administered during 28 days</description>
    <arm_group_label>Cyclosporine low dose , Prednisolone Acetate</arm_group_label>
    <arm_group_label>Cyclosporine low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PA</intervention_name>
    <description>Suspension of Prednisolone Acetate administered during 28 days</description>
    <arm_group_label>Cyclosporine low dose , Prednisolone Acetate</arm_group_label>
    <arm_group_label>Cyclosporine high dose, Prednisolone Acetate</arm_group_label>
    <arm_group_label>Prednisolone Acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution administered during 28 days</description>
    <arm_group_label>Cyclosporine high dose</arm_group_label>
    <arm_group_label>Cyclosporine low dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of ocular allergies and a positive skin test reaction to perennial allergens
             within the past 24 months and a history of chronic eye irritation

          -  visual acuity score â‰¥ 0.60 (EDTS)

          -  negative urine pregnancy test for female patients, and use of adequate birth control
             throughout the study period.

        Exclusion Criteria:

          -  active ocular infection; preauricular lymphadenopathy or ocular condition that could
             affect study; glaucoma or abnormal intraocular pressure; ocular surgery within past 3
             months; history of asthma, pregnancy or nursing

          -  contraindications or known allergies to the study drug(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Louise Jacques, MD MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Fovea Pharmaceuticals SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ORA</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

